Simplified Chinese
Du Weimin supports the enactment of the Vaccine Administration Law, helping to build a protective barrier for public health.
Release date:
2019-07-18
Author:
Source:
Text/Excerpt by Xia Jiu Ke Chui Zhuo
Abstract
Recently, the Vaccine Administration Law was adopted at the 11th Meeting of the Standing Committee of the 13th National People’s Congress. This marks the first dedicated legislation in China’s vaccine‑administration field, and the law will officially come into force on December 1, 2019.
It is reported that the Vaccine Administration Law stipulates that the state shall implement the strictest regulatory regime for vaccines, establishing special systems and provisions covering the entire process—from research and development, through production and distribution, to vaccination.
With the new Vaccine Law now in effect, how will listed companies respond? On June 28, Du Weimin, Chairman and President of Kangtai Biological, stated at the groundbreaking ceremony for the company’s new headquarters that Kangtai Biological supports the state’s efforts to strengthen oversight across the entire vaccine lifecycle—production, distribution, and immunization—and has made thorough preparations to welcome the formal implementation of the Vaccine Management Law, working together to build a robust safeguard for the health and well-being of the public.
According to Du Weimin, as a leading company in the vaccine sector, Kangtai Biological has been involved since the very inception of the Vaccine Administration Law. In mid-November last year, it also submitted well‑reasoned suggestions for revisions to the draft of the law. He stated that Kangtai Biological has long since established an information‑based vaccine traceability system and upholds the principle that “quality is life” throughout its entire value chain, with a 100% approval rate for batch release of its hepatitis B vaccine.
Even prior to the passage of the Vaccine Administration Law, on April 18, 2019, Kangtai Biological, as one of the initiating entities, joined two other vaccine manufacturers based in Guangdong Province to convene the “Founding Meeting of the Guangdong Vaccine Industry Self‑Regulation Mechanism,” establishing the “Guangdong Vaccine Industry Self‑Regulatory Organization.” The parties jointly signed the “Vaccine Self‑Regulation Agreement,” advocating the creation of a new model of social governance characterized by “joint development, joint governance, and shared benefits” within the vaccine industry. The signing ceremony for this self‑regulation agreement took place at Kangtai Biological’s headquarters, with relevant leaders from the Guangdong Provincial Drug Administration and the Shenzhen Municipal Market Supervision Administration serving as witnesses.
It is reported that the Vaccine Administration Law encourages vaccine manufacturers to produce and export vaccines in accordance with international procurement standards. Du Weimin revealed that as early as February 2018, Minhai Biologics, a subsidiary of Kangtai Biological, had already exported one million doses of measles vaccine concentrate to Pakistan’s National Institute of Health.
Earlier this year, Minhai Biologics once again supplied Pakistan with 1 million doses of measles vaccine concentrate, becoming the first company to export such a product to the country. Meanwhile, to expand the international reach of domestically produced vaccines, Kangtai Biological is actively pursuing international regulatory approvals at several production facilities in Shenzhen and Beijing.
In terms of upgrading its infrastructure, Kangtai Biological has also been actively making strides. At the recent groundbreaking ceremony for the company’s new headquarters campus, Du Weimin revealed that the site will be developed into an integrated complex encompassing R&D, incubation, office space, and exhibition facilities, with a total investment of RMB 2 billion and a footprint of 17,300 square meters—featuring a 37‑story R&D building.
In October 2018, Kangtai Biological’s global vaccine R&D and manufacturing base—costing 850 million yuan and spanning over 60,000 square meters—was officially commissioned. The facility is the largest single‑building vaccine production site in Asia, providing an optimal environment for vaccine research and development, safe production, quality testing, and storage.
In the industry, Kangtai Biological is widely recognized for its strong R&D capabilities and robust product pipeline, and has recently been assigned “Buy” ratings by several brokerage firms. In early December 2018, Kangtai Biological announced that it had received approval from the Shenzhen Science and Technology Association to establish an academician workstation. Academician Hou Yunde, winner of the 2017 State Supreme Science and Technology Award and former Vice President of the Chinese Academy of Engineering, joined as an in‑station academician and Kangtai Biological’s Chief Scientist, helping the company build a long‑term industry–university–research collaboration framework and enhancing its technological innovation capacity and overall competitiveness in the field of next‑generation vaccines. To date, Kangtai Biological operates multiple national key laboratories and R&D centers, has established eight academician and expert workstations and other R&D platforms, and has forged an R&D structure characterized by “South Kangtai” and “North Minhai.” The company has also undertaken projects under the National Torch Program and the 863 Major Scientific Research Program, comprehensively elevating its innovation capabilities and R&D standards.
Like many traditional enterprises committed to public health, Kangtai Biological has long worked quietly and unassumingly. Over more than 30 years of development, it has grown into a national high-tech company with a comprehensive portfolio of R&D products, a rich product pipeline, and distinct technological advantages, holding a pivotal position in China’s national immunization program. In the case of the hepatitis B vaccine alone, Kangtai Biological has produced and sold over one billion doses, helping more than 300 million people avoid infection by the hepatitis B virus.
Recommended Reading
Batch Release Status of the Company’s Products in 2026
2026-07-23
2026-07-15
2026-07-09
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account